Stocks News 2 November 2025

Palantir Stock Skyrockets 150% – Inside the AI Defense Giant’s Epic 2025 Rally

Company Background and Business Model Palantir Technologies is a pioneering data analytics and software company founded in 2003 by Peter Thiel, CEO Alex Karp, and others. Originally known for its work with U.S. intelligence agencies, Palantir built its reputation developing

5 November 2025

COMPASS Pathways (CMPS) Psychedelic Breakthrough Stock – Latest News, Analysis & 2025 Outlook

Below is a full breakdown of COMPASS Pathways’ recent performance, news, expert commentary, industry positioning, and an analysis of the stock’s fundamentals, technicals, and future scenarios. Stock Performance Overview (Nov 2025) COMPASS Pathways’ stock has experienced considerable volatility in 2025,

4 November 2025

Biotechnology · Investing · Market Analysis · NASDAQ:CMPS · Psychedelics · Stocks

Dave Inc. (DAVE) Stock – Fintech Underdog Turned Wall Street Rocket

Current Stock Price & Recent Performance Dave Inc.’s stock has been on a tear in 2025. Shares currently trade around $264 as of November 4, 2025, after spiking nearly 10% on the morning of its earnings release stockanalysis.com. This jump

4 November 2025

Company Analysis · Fintech · Investing · NASDAQ:DAVE · Stocks · Wall Street

Ondas Holdings (ONDS) Stock Skyrockets 770% – Huge Deals, Price Swings & 2025 Outlook

Current Stock Price & Recent Performance Chart: ONDS daily closing price, Sep–Nov 2025. After a meteoric rise in early October, the stock has retraced to the mid-$6 range. Ondas Holdings’ stock has experienced a roller coaster ride in recent weeks.

4 November 2025

2025 Outlook · Financial Analysis · Investing · Market News · NASDAQ:ONDS · Stocks

Marriott Stock Skyrockets on Luxury Travel Boom – Full 2025 Outlook & Analysis

Now let’s dive deeper into each of these areas and what they mean for investors considering Marriott stock in late 2025. Latest News: Earnings Beat and Forecast Boost Marriott’s third-quarter 2025 earnings (released November 4) provided a dose of good

4 November 2025

Investment · Luxury Travel · Market Analysis · NASDAQ:MAR · Stocks · Travel Industry

Palantir Stock Whipsaws After ‘Otherworldly’ Q3—Has the 400% AI Rally Finally Met Its Match?

Key facts (Nov 4, 2025) What’s happening today (4.11.2025) Palantir (NASDAQ: PLTR) swung lower in early U.S. trading despite recording another blockbuster quarter and hiking guidance, as investors reassessed lofty AI valuations after a year‑long melt‑up. Pre‑market quotes showed the

4 November 2025

AI · Earnings · Market Trends · NASDAQ:PLTR · Stocks · Technology

Kimberly-Clark’s $40 Billion Gamble Sends KMB Stock Plunging – What’s Next for This Dividend King?

Real-Time Stock Price & Recent Performance As of November 4, 2025, Kimberly-Clark’s stock is trading around $102 per share, near its 52-week low. The current price reflects a dramatic sell-off that occurred on Monday, Nov 3, when KMB plunged from

4 November 2025

Dividends · Financial News · Investing · Market Analysis · Stocks

CURE Pharmaceutical (CURR) Stock Skyrockets Amid Wellness Pivot – What’s Next for Investors?

High-Flying Share Price and Recent Performance 🚀 As of November 3, 2025, CURE Pharmaceutical’s stock is trading around $3.6 per share, reflecting an explosive rise in late October. On Friday, Oct 31, the stock closed at $3.78, up from $2.89

3 November 2025

Investing · Market Analysis · Pharmaceutical Industry · Stocks · Wellness

TG Therapeutics Stock Soars on Briumvi Boom – Key Facts, Analyst Insights & 2025 Outlook

Company Overview: Briumvi-Focused Business Model TG Therapeutics, Inc. is a commercial-stage biopharmaceutical company specializing in treatments for B-cell mediated diseases gurufocus.com. After years as a development-stage biotech, TG entered the commercial arena with Briumvi, its first approved product, and now

3 November 2025

Biotech · Healthcare · Investment · Market Analysis · NASDAQ:TGTX · Stocks

Pfizer (PFE) Stock at a Crossroads: Big Dividend, Weight-Loss Gamble & 2025 Outlook

Stock Price and Recent Performance Pfizer’s stock has languished in 2025 despite a rising broader market. At ~$24.65, PFE is roughly flat since January and far below its 2021 peak (~$50) sharewise.com. In the past three years, the shares have

3 November 2025

Dividends · Investment Strategies · Market Outlook · NYSE:PFE · Pharmaceuticals · Stocks

Palantir Stock Skyrockets on Massive UK AI-Defense Pact – Could PLTR Eclipse Oracle by 2030?

Palantir Stock Skyrockets to New Highs: Inside PLTR’s AI-Fueled Surge and What’s Next

Detailed Report Palantir Stock Soars to Record Highs Ahead of Earnings Palantir’s stock price has been on a tear, surging to new all-time highs as of early November 2025. As of November 3, 2025, PLTR trades around $200 per share,

3 November 2025

Artificial Intelligence · Investment · Market Analysis · NASDAQ:PLTR · Stocks · Technology

Pfizer Stock Surges on Trump Deal & Obesity Drug Drama – Is a Comeback Coming?

Company Background & Significance Founded in 1849, Pfizer Inc. has grown into a pillar of the pharmaceutical industry, known for landmark drugs and vaccines. From breakthrough treatments like Lipitor (cholesterol) and Viagra (ED), to its 2020 partnership with BioNTech delivering

2 November 2025

Health Industry · Investing · Market News · NYSE:PFE · Pharmaceuticals · Stocks

Stocks News 2 November 2025 - 5 November 2025